Combination of vaccination and inhibition of the PD-1 pathway
The present invention relates to a vaccine/inhibitor combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and a composition comprising at least one PD-1 pathway inhibitor, preferably directed against PD-1 receptor or its ligands PD-L1 and PD-L2. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/inhibitor combination. Additionally the present invention relates to medical use of such a vaccine/inhibitor combination, the pharmaceutical composition and the kit of parts comprising such a vaccine/inhibitor combination, particularly for the prevention or treatment of tumor or cancer diseases or infectious diseases. Furthermore, the present invention relates to the use of an RNA vaccine in therapy in combination with a PD-1 pathway inhibitor and to the use of a PD-1 pathway inhibitor in therapy in combination with an RNA vaccine.
1. A method of treating a subject having a cancer or a tumor disease, the method comprising administering to the subject an effective amount of:
(i) an immunogenic composition comprising at least one mRNA comprising at least one open reading frame (ORF) encoding at least one tumour-specific antigen (TSA), or an antigenic fragment of a TSA, wherein said mRNA comprises a 5′ Cap and a Poly-A sequence of about 25 to about 400 adenosine nucleotides; and
(ii) a PD-1 pathway inhibitor, said PD-1 pathway inhibitor comprising an antagonistic antibody directed against PD-1 or PD-L1.
2. The method of claim 1 , wherein the tumour-specific antigen (TSA) consists of one antigenic one epitope.
3. The method of claim 1 , wherein the tumour-specific antigen (TSA) comprises multiple antigenic epitopes.
4. The method of claim 1 , wherein the tumour-specific antigen (TSA) results from a tumour specific mutation.
5. The method of claim 1 , wherein the tumour-specific antigen (TSA) results from a tumour specific mutation in a tumor antigen selected from the group consisting of 5T4, 707-AP, 9D7, AFP, AlbZIP HPG1, alpha-5-beta-l-integrin, alpha-5-beta-6-integrin, alpha-actinin-4, alpha-methylacyl-coenzyme A racemase, ART-4, ARTC1, B7H4, BAGE-1, BCL-2, bcr/abl, beta-catenin, BING-4, BRCA1, BRCA2, CA 15-3/CA 27-29, CA 19-9, CA72-4, CA125, calreticulin, CAMEL, CASP-8, cathepsin B, cathepsin L, CD19, CD20, CD22, CD25, CDE30, CD33, CD4, CD52, CD55, CD56, CD80, CDC27, CDK4, CDKN2A, CEA, CLCA2, CML28, CML66, COA-1, coactosin-like protein, collage XXIII, COX-2, CT-9/BRD6, Cten, cyclin B1, cyclin D1, cyp-B, CYPB1, DAM-10, DAM-6, DEK-CAN, EFTUD2, EGFR, ELF2, EMMPRIN, EpCam, EphA2, EphA3, ErbB3, ETV6-AML1, EZH2, FGF-5, FN, Frau-1, G250, GAGE-1, GAGE-2, GAGE-3, GAGE-4, GAGE-5, GAGE-6, GAGE7b, GAGE-8, GDEP, GnT-V, gp100, GPC3, GPNMB, HAGE, HAST-2, hepsin, Her2/neu, HERV-K-MEL, HLA-A*0201-R17I, HLA-A11, HLA-A2, HNE, homeobox NKX3.1, HOM-TES-14/SCP-1, HOM-TES-85, HPV-E6, HPV-E7, HSP70-2M, HST-2, hTERT, iCE, IGF-1R, IL-13Ra2, IL-2R, IL-5, immature laminin receptor, kallikrein-2, kallikrein-4, Ki67, KIAA0205, KIAA0205/m, KK-LC-1, K-Ras, LAGE-A1, LDLR-FUT, MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A6, MAGE-A9, MAGE-A10, MAGE-A12, MAGE-B1, MAGE-B2, MAGE-B3, MAGE-B4, MAGE-B5, MAGE-B6, MAGE-B10, MAGE-B16, MAGE-B17, MAGE-C1, MAGE-C2, MAGE-C3, MAGE-D1, MAGE-D2, MAGE-D4, MAGE-E1, MAGE-E2, MAGE-F1, MAGE-H1, MAGEL2, mammaglobin A, MART-1/melan-A, MART-2, MART-2, matrix protein 22, MC1R, M-CSF, ME1, mesothelin, MG50/PXDN, MMP11, MN/CA IX-antigen, MRP-3, MUC-1, MUC-2, MUM-1, MUM-2, MUM-3, myosin class I, NA88-A, N-acetylglucosaminyltransferase-V, Neo-PAP, Neo-PAP, NFYC, NGEP, NMP22, NPM/ALK, N-Ras, NSE, NY-ESO-B, NY-ESO-1, OA1, OFA-iLRP, OGT, OGT, OS-9, OS-9, osteocalcin, osteopontin, p15, p190 minor bcr-abl, p53, p53, PAGE-4, PAI-1, PAI-2, PAP, PART-1, PATE, PDEF, Pim-1-Kinase, Pin-1, Pml/PARalpha, POTE, PRAME, PRDX5, prostein, proteinase-3, PSA, PSCA, PSGR, PSM, PSMA, PTPRK, RAGE-1, RBAF600, RHAMM/CD168, RU1, RU2, S-100, SAGE, SART-1, SART-2, SART-3, SCC, SIRT2, Sp17, SSX-1, SSX-2/HOM-MEL-40, SSX-4, STAMP-1, STEAP-1, survivin, survivin-2B, SYT-SSX-1, SYT-SSX-2, TA-90, TAG-72, TARP, TEL-AML1, TGFbeta, TGFbetaRII, TGM-4, TPI, TRAG-3, TRG, TRP-1, TRP-2/6b, TRP/INT2, TRP-p8, tyrosinase, UPA, VEGFR1, VEGFR-2/FLK-1, and WT1.
6. The method of claim 1 , wherein the tumour-specific antigen (TSA) is selected from the group consisting of alpha-actinin-4, bcr/abl, beta-catenin, BRCA1, BRCA2, CASP-8, CDC27, CDK4, CDKN2A, COA-1, EFTUD2, ELF2, GPNMB, HLA-A*0201-R17I, HLA-A11, HLA-A2, KIAA0205, K-Ras, MART-2, ME1, MUM-1, MUM-2, MUM-3, myosin class I, Neo-PAP, NFYC, N-Ras, OGT, OS-9, p190 minor bcr-abl, p53, PRDX5, PTPRK, RBAF600, SIRT2, TPI.
7. The method of claim 1 , wherein the at least one open reading frame is codon optimized for the human codon usage.
8. The method of claim 1 , wherein the at least one open reading frame of the at least one mRNA comprises an increased G/C content relative to the open reading frame of a wild type mRNA encoding the tumour-specific antigen (TSA).
9. The method of claim 1 , wherein the at least one mRNA is chemically modified.
10. The method of claim 1 , wherein the at least one open reading frame (ORF) encodes at least two different epitopes of at least two different tumour-specific antigens (TSA).
11. The method of claim 1 , wherein the immunogenic composition comprises at least two different mRNAs each comprising at least one open reading frame (ORF) encoding different tumour-specific antigens (TSA).
12. The method of claim 1 , wherein the at least one mRNA is complexed with a carrier.
13. The method of claim 12 , wherein the carrier is a cationic, polycationic or polymeric carrier.
14. The method of claim 12 , wherein the carrier comprises protamine.
15. The method of claim 12 , wherein the carrier comprises a cationic or polycationic lipid.
16. The method of claim 1 , wherein the PD-1 pathway inhibitor is administered after said immunogenic composition.
17. The method of claim 1 , wherein the immunogenic composition and the PD-1 pathway inhibitor are administered sequentially.
18. The method of claim 1 , wherein the immunogenic composition and the PD-1 pathway inhibitor are administered concurrently.
19. The method of claim 1 , wherein the immunogenic composition and the PD-1 pathway inhibitor are administered via different administration routes.
20. The method of claim 11 , wherein said two different RNAs encode:
i) NY-ESO-1, or an antigenic fragment thereof; and
ii) MAGE-A3, or an antigenic fragment thereof.
21. The method of claim 20 , wherein said two different RNAs encode:
i) NY-ESO-1; and
ii) MAGE-A3.
22. The method of claim 20 , wherein the immunogenic composition further comprises a mRNA encoding tyrosinase, or an antigenic fragment thereof.
23. The method of claim 20 , wherein the PD-1 pathway inhibitor is an anti-PD1 antibody.
24. The method of claim 23 , wherein the subject has a melanoma.
25. The method of claim 24 , wherein the immunogenic composition is administered by intravenous injection.